David Nguyen
Long Beach, CANPI 1063737740
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$29,874,846in research payments, 2019–2025
Across 234 payments — averaging $127,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amphastar Pharmaceuticals, Inc.$9.1M
- Eli Lilly$5M
- Noven Pharmaceuticals, Inc.$3.9M
- Pfizer$3.1M
- Takeda Pharmaceuticals U.S.A., Inc.$2.7M
- Janssen Research & Development, LLC$2.3M
- plus $3.7M from 6 others
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.